Brief: Kancera Receives Patent Grant In US For The Drug Candidate KAND145

Novakand Pharma AB

25/05/2022 07:36

May 25 (Reuters) - Kancera AB  KANC.ST :
    * KANCERA RECEIVES PATENT GRANT IN US FOR THE DRUG CANDIDATE
KAND145
    * US PATENT OFFICE (USPTO) HAS ISSUED A PATENT THAT PROTECTS
CHEMICAL STRUCTURE OF KANCERA'S FRACTALKINE BLOCKER KAND145.
    * THIS PATENT, US 11,339,183, IS OWNED BY KANCERA AND IS
VALID
THROUGH 2039.

Source text for Eikon:  ID:nMFNczJQ6 
Further company coverage:  KANC.ST 

 (Gdansk Newsroom)
 ((Gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))